MedPath

Tagged News

Samsung Bioepis Partners with Phrontline to Develop Next-Generation Dual-Payload ADCs for Cancer Treatment

OncologyPrecision Medicine
  • Samsung Bioepis and Phrontline Biopharma have entered a global collaboration to co-develop two investigational antibody-drug conjugate assets, including TJ108, targeting EGFR and HER3 receptors overexpressed in various cancers.
  • The partnership introduces bispecific, dual-payload ADC therapeutics designed to overcome limitations of current single-payload, single-target ADCs, particularly addressing resistance, tumor heterogeneity, and durability challenges.
  • Samsung Bioepis will receive exclusive licensing rights for a topoisomerase-1 inhibitor payload and expand its oncology portfolio beyond biosimilars into innovative drug development.
  • TJ108 utilizes Phrontline's dual-linker payload platform to simultaneously deliver two payloads with complementary mechanisms of action through branched-linker architecture for enhanced therapeutic efficacy.

The Jackson Laboratory Acquires New York Stem Cell Foundation to Accelerate Precision Medicine Discovery

Precision MedicineAIDrug Discovery
  • The Jackson Laboratory has completed its acquisition of the New York Stem Cell Foundation, creating a powerful nonprofit platform that combines genetics, stem cell science, and AI-driven analytics for biomedical discovery.
  • The integration merges JAX's mouse modeling expertise with NYSCF's Global Stem Cell Array® robotic platform, enabling large-scale, reproducible stem cell research and patient-specific disease modeling.
  • This unified platform aims to accelerate therapeutic development for diseases including Alzheimer's, ALS, cancer, diabetes, and Parkinson's by improving early-stage research predictability and reducing clinical trial failures.

Pfizer's BRAFTOVI Plus MEKTOVI Achieves Nearly Four-Year Survival in BRAF-Mutant Lung Cancer

Targeted TherapyPrecision Medicine
  • Pfizer's BRAFTOVI plus MEKTOVI combination therapy demonstrated a median overall survival of 47.6 months in treatment-naïve patients with BRAF V600E-mutant metastatic non-small cell lung cancer.
  • The Phase 2 PHAROS trial showed four-year overall survival rates of 49% for treatment-naïve patients and 31% for previously treated patients after approximately four years of follow-up.
  • The combination therapy achieved an objective response rate of 75% in treatment-naïve patients and 46% in previously treated patients with this rare lung cancer subtype.
  • These results potentially establish a new benchmark for targeted therapies in BRAF V600E-mutant metastatic NSCLC, a mutation found in approximately 2% of lung cancer cases.

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

NCT04956640RecruitingPhase 1
Eli Lilly and Company
Posted 7/19/2021

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

NCT03915951CompletedPhase 2
Pfizer
Posted 6/4/2019

A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer

NCT04036682Active, Not RecruitingPhase 1
Cullinan Therapeutics Inc.
Posted 10/31/2019

Oncodesign Precision Medicine Secures €250,000 Regional Grant to Advance Cancer Drug Development

Precision MedicineAI
  • Oncodesign Precision Medicine received a €250,000 investment grant from the Bourgogne Franche-Comté Region to strengthen its technological and scientific capabilities in precision medicine.
  • The funding will support development of the company's innovative drug candidates targeting chronic inflammatory digestive diseases, immuno-oncology, and Parkinson's disease.
  • OPM currently has two kinase inhibitors in clinical development, with OPM-101 scheduled to begin phase 1b/2a oncology trials in September 2025.
  • The company's Nanocyclix® platform has generated a library of 12,000 macrocyclic kinase inhibitor molecules, with AI integration planned to accelerate drug discovery.

Indivi and Clouds of Care Partner to Advance Deep Phenotyping Technologies for Alzheimer's and Parkinson's Drug Development

Precision Medicine
  • Two TechBio companies, Indivi and Clouds of Care, announced a strategic partnership to advance precision medicine tools in early-phase neuroscience drug development for Alzheimer's and Parkinson's disease.
  • The collaboration integrates neuro-electrophysiology expertise with digital health technology tools to establish a unified framework for multimodal deep phenotyping in clinical trials.
  • The partnership aims to improve drug development success rates by increasing signal-to-noise ratio of endpoints and delivering earlier Proof-of-Biology and Proof-of-Concept signals.
  • The initiative aligns with the European Medicines Agency's recent call for updated guidelines on early Alzheimer's trials, emphasizing more responsive and clinically meaningful endpoints.

Lunit's AI Platform Demonstrates Predictive Power for Immunotherapy Response Across Multiple Cancer Types at ESMO 2025

AIPrecision Medicine
  • Lunit's SCOPE IO artificial intelligence platform successfully predicted immunotherapy response in three major cancer types through analysis of routine histopathology slides presented at ESMO 2025.
  • In colorectal cancer trials, biomarker-high patients showed significantly improved progression-free survival and overall survival when treated with atezolizumab combinations compared to biomarker-low patients.
  • The AI tool demonstrated 60.5% response rates versus 23.2% for inflamed versus non-inflamed tumors in advanced clear cell renal cell carcinoma patients treated with nivolumab plus ipilimumab.
  • Validation studies across lung, kidney, and colorectal cancers support the platform's potential to guide personalized immunotherapy treatment selection in clinical practice.

AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients

NCT04513951CompletedPhase 2
Gruppo Oncologico del Nord-Ovest
Posted 4/1/2020

FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients

NCT03721653CompletedPhase 2
Gruppo Oncologico del Nord-Ovest
Posted 11/30/2018

Neutrolis to Present Early Human Proof-of-Concept Data for Novel NET-Targeting Therapy at ACR 2025

Precision Medicine
  • Neutrolis will present late-breaking clinical data on NTR-441, an albumin-DNASE1L3 fusion protein designed to target Neutrophil Extracellular Traps (NETs) in systemic lupus erythematosus patients with DNASE1L3 deficiency.
  • The presentation at ACR Convergence 2025 will showcase early evidence of human proof-of-concept for the company's exDNASE therapeutic platform, marking a significant milestone in NET-targeting therapy development.
  • Unlike conventional immunosuppressive approaches, NTR-441 aims to provide rapid clinical effects by precisely degrading pathogenic NETs without broadly suppressing immune responses.
  • The therapy represents a potential new class of disease-modifying treatments for inflammatory disorders including lupus and rheumatoid arthritis, addressing high unmet medical needs in these conditions.

Phase 1 Study to Assess Safety, Tolerability, PD, PK, Immunogenicity of IV NTR-441 Solution in Healthy Volunteers and COVID-19 Patients

NCT04941183TerminatedPhase 1
Neutrolis
Posted 4/14/2021

Natera's Signatera MRD Test Shows Promise in Guiding Bladder Cancer Treatment at ESMO 2025

Precision Medicine
  • Natera will present 14 studies at ESMO 2025, including six oral presentations highlighting Signatera's expanding role in molecular residual disease testing across multiple cancer types.
  • The IMvigor011 trial demonstrates Signatera's ability to predict disease-free survival and overall survival benefits from adjuvant atezolizumab in muscle-invasive bladder cancer patients.
  • CheckMate 274 trial results show that Signatera-positive patients treated with nivolumab had more than doubled disease-free survival compared to placebo (7.4 vs 2.8 months).
  • The presentations underscore the growing impact of bespoke MRD assessment in personalizing cancer treatment recommendations and improving patient outcomes.

Biokin Pharmaceutical Receives NMPA Approval for First-in-Class Radiopharmaceutical [177Lu]-BL-ARC001

Drug ApprovalOncologyPrecision Medicine
  • Biokin Pharmaceutical received NMPA approval for clinical trials of [177Lu]-BL-ARC001, marking the company's entry into the radiopharmaceutical drug conjugate field.
  • C-Ray Therapeutics completed process development and quality studies in five months using China's first fully automated GMP-grade radiopharmaceutical production line.
  • The approval represents a significant milestone as Chinese pharmaceutical companies expand from ADCs and bispecifics into RDCs, advancing integrated diagnosis and therapy approaches.
  • Biokin joins leading Chinese companies including Kelun, Hengrui, Yunnan Baiyao, and Fosun in pushing China's radiopharmaceutical industry toward a new era of precision medicine.

Singapore Opens New Clinical Trial Centre for Precision Geromedicine at NUS Medicine

Precision Medicine
  • Singapore has unveiled a 350-square-meter Clinical Trial Centre at NUS Medicine dedicated to translating geroscience into clinical practice through precision geromedicine approaches.
  • The facility employs a multimodal approach combining biomarker-driven diagnostics, digital monitoring, and systems biology to tailor interventions based on individual biological age and health trajectories.
  • Current trials include PROMETHEUS combining exercise and lifestyle coaching, SIRT6 Activator exploring DNA-repair potential of fucoidan, and CEDIRA examining multivitamin effects on biological age.
  • The centre integrates research with education to train clinician-scientists while addressing the gap between biomarker discovery and real-world intervention in aging research.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.